sk&f-38393 has been researched along with Atherosclerotic Parkinsonism in 25 studies
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine: A selective D1 dopamine receptor agonist used primarily as a research tool.
1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1 and two hydroxy substituents at positions 7 and 8.
SKF 38393 : A racemate comprising equimolar amounts of (R)- and (S)-SKF 38393
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced parkinsonian symptoms, predominantly bradykinesia and tremor, in marmosets." | 3.67 | Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. ( Close, SP; Marriott, AS; Pay, S, 1985) |
| "Dextromethorphan has been reported to be a weak antagonist of the ion channel associated with the NMDA receptor, and to have putative antiparkinsonian activity in man." | 1.29 | Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse. ( Kaur, S; Starr, MS, 1995) |
| "Treatment with bromocriptine (5 mg/kg) relieved the parkinsonian symptoms, but the efficacy of this treatment appeared to decrease slightly with time." | 1.28 | Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393. ( Bédard, PJ; Di Paolo, T; Rouillard, C, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (20.00) | 18.7374 |
| 1990's | 18 (72.00) | 18.2507 |
| 2000's | 1 (4.00) | 29.6817 |
| 2010's | 1 (4.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carta, AR | 1 |
| Frau, L | 1 |
| Pinna, A | 1 |
| Morelli, M | 4 |
| Simola, N | 1 |
| Fenu, S | 2 |
| Baraldi, PG | 1 |
| Tabrizi, MA | 1 |
| Kaur, S | 1 |
| Starr, MS | 1 |
| Engber, TM | 1 |
| Papa, SM | 1 |
| Boldry, RC | 1 |
| Chase, TN | 2 |
| Sato, K | 1 |
| Ueda, H | 1 |
| Okumura, F | 1 |
| Misu, Y | 1 |
| Calabresi, P | 1 |
| Mercuri, NB | 1 |
| Sancesario, G | 1 |
| Bernardi, G | 1 |
| Yoshimura, N | 1 |
| Mizuta, E | 1 |
| Kuno, S | 1 |
| Sasa, M | 1 |
| Yoshida, O | 1 |
| Nikkhah, G | 1 |
| Duan, WM | 1 |
| Knappe, U | 1 |
| Jödicke, A | 1 |
| Björklund, A | 1 |
| Kashihara, K | 1 |
| Akiyama, K | 1 |
| Ishihara, T | 1 |
| Shiro, Y | 1 |
| Shohmori, T | 1 |
| Andringa, G | 1 |
| Vermeulen, RJ | 1 |
| Drukarch, B | 1 |
| Stoof, JC | 1 |
| Cools, AR | 1 |
| Huang, KX | 1 |
| Bergstrom, DA | 1 |
| Ruskin, DN | 1 |
| Walters, JR | 1 |
| Oh, JD | 1 |
| Vaughan, CL | 1 |
| Gresch, PJ | 1 |
| Walker, PD | 1 |
| Elliott, PJ | 1 |
| Walsh, DM | 1 |
| Close, SP | 2 |
| Kebabian, JW | 1 |
| Britton, DR | 1 |
| DeNinno, MP | 1 |
| Perner, R | 1 |
| Smith, L | 1 |
| Jenner, P | 3 |
| Schoenleber, R | 1 |
| Williams, M | 1 |
| Di Chiara, G | 2 |
| Miller, R | 1 |
| Beninger, RJ | 1 |
| Boyce, S | 1 |
| Rupniak, NM | 1 |
| Steventon, MJ | 1 |
| Iversen, SD | 1 |
| Rouillard, C | 1 |
| Bédard, PJ | 3 |
| Di Paolo, T | 2 |
| Boucher, R | 2 |
| Marsden, CD | 2 |
| Nomoto, M | 1 |
| Falardeau, P | 1 |
| Bouchard, S | 1 |
| Marriott, AS | 1 |
| Pay, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Namenda as Prevention for Post-Operative Delirium[NCT00303433] | Phase 4 | 30 participants | Interventional | 2006-03-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for sk&f-38393 and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
On the interpretation of asymmetries of posture and locomotion produced with dopamine agonists in animals with unilateral depletion of striatal dopamine.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Amphetamine; Animals; Apomorphine; Benza | 1991 |
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1986 |
23 other studies available for sk&f-38393 and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Corpus Striatum; Dopamine Agoni | 2010 |
Blockade of globus pallidus adenosine A(2A) receptors displays antiparkinsonian activity in 6-hydroxydopamine-lesioned rats treated with D(1) or D(2) dopamine receptor agonists.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adenosine A2 Receptor Antagonists; Anima | 2008 |
Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Behavior, | 1995 |
NMDA receptor blockade reverses motor response alterations induced by levodopa.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Dizocilpine Maleate; Levodopa; | 1994 |
Supersensitization of intrastriatal dopamine receptors involved in opposite regulation of acetylcholine release in Parkinson's model rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Acetylcholine; Animals; Benzazepines; Do | 1994 |
Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; 6-Cyano-7-nitroquinoxaline-2,3-dione; Ac | 1993 |
The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1993 |
Restoration of complex sensorimotor behavior and skilled forelimb use by a modified nigral cell suspension transplantation approach in the rat Parkinson model.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; | 1993 |
Levodopoa but not bromocriptine induces AP-1 and creb DNA-binding activity in the dopamine-depleted striatum of the rat.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Base Sequ | 1996 |
Dopamine receptor subtypes as targets for the pharmacotherapy of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1998 |
N-methyl-D-aspartate receptor blockade attenuates D1 dopamine receptor modulation of neuronal activity in rat substantia nigra.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Corpus Striatum; | 1998 |
Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antibodies; Antiparkinson Agent | 1999 |
Synergistic interaction between serotonin-2 receptor and dopamine D1 receptor stimulation on striatal preprotachykinin mRNA expression in the 6-hydroxydopamine lesioned rat.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Amphetamines; Animals; Chromatography, H | 1999 |
Dopamine D1 and D2 receptor interactions in the MPTP-treated marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1992 |
A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1992 |
Blockade of N-methyl-D-aspartate receptors potentiates dopaminergic responses in the 6-OHDA model of Parkinson: differential role of D-1 and D-2 receptors.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Caudate Nucleus; Dizocilpine Ma | 1992 |
MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benserazide; Dizocilpine Maleat | 1990 |
Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1990 |
Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1990 |
Effect of D1 receptor stimulation in normal and MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1989 |
The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1985 |
Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1988 |
Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1985 |